Cargando…
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459474/ https://www.ncbi.nlm.nih.gov/pubmed/30973957 http://dx.doi.org/10.1371/journal.pone.0215491 |
| _version_ | 1783410183554203648 |
|---|---|
| author | Motoya, Satoshi Watanabe, Kenji Ogata, Haruhiko Kanai, Takanori Matsui, Toshiyuki Suzuki, Yasuo Shikamura, Mitsuhiro Sugiura, Kenkichi Oda, Kazunori Hori, Tetsuharu Araki, Takahiro Watanabe, Mamoru Hibi, Toshifumi |
| author_facet | Motoya, Satoshi Watanabe, Kenji Ogata, Haruhiko Kanai, Takanori Matsui, Toshiyuki Suzuki, Yasuo Shikamura, Mitsuhiro Sugiura, Kenkichi Oda, Kazunori Hori, Tetsuharu Araki, Takahiro Watanabe, Mamoru Hibi, Toshifumi |
| author_sort | Motoya, Satoshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6459474 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-64594742019-05-03 Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study Motoya, Satoshi Watanabe, Kenji Ogata, Haruhiko Kanai, Takanori Matsui, Toshiyuki Suzuki, Yasuo Shikamura, Mitsuhiro Sugiura, Kenkichi Oda, Kazunori Hori, Tetsuharu Araki, Takahiro Watanabe, Mamoru Hibi, Toshifumi PLoS One Correction Public Library of Science 2019-04-11 /pmc/articles/PMC6459474/ /pubmed/30973957 http://dx.doi.org/10.1371/journal.pone.0215491 Text en © 2019 Motoya et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Motoya, Satoshi Watanabe, Kenji Ogata, Haruhiko Kanai, Takanori Matsui, Toshiyuki Suzuki, Yasuo Shikamura, Mitsuhiro Sugiura, Kenkichi Oda, Kazunori Hori, Tetsuharu Araki, Takahiro Watanabe, Mamoru Hibi, Toshifumi Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study |
| title | Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study |
| title_full | Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study |
| title_fullStr | Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study |
| title_full_unstemmed | Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study |
| title_short | Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study |
| title_sort | correction: vedolizumab in japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459474/ https://www.ncbi.nlm.nih.gov/pubmed/30973957 http://dx.doi.org/10.1371/journal.pone.0215491 |
| work_keys_str_mv | AT motoyasatoshi correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT watanabekenji correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT ogataharuhiko correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT kanaitakanori correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT matsuitoshiyuki correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT suzukiyasuo correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT shikamuramitsuhiro correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT sugiurakenkichi correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT odakazunori correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT horitetsuharu correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT arakitakahiro correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT watanabemamoru correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy AT hibitoshifumi correctionvedolizumabinjapanesepatientswithulcerativecolitisaphase3randomizeddoubleblindplacebocontrolledstudy |